43 - What’s New with VRE

Thursday, September 30, 2021

3:45 PM - 5:00 PM EDT

Moderator(s)

Julia Messina, MD, MHS, MS

Assistant Professor
Medicine
Duke University
Durham, North Carolina, United States

Uptodate (Individual(s) Involved: Self): Author, Other Financial or Material Support
Truc Cecilia Tran, PharmD

Assistant Professor
UTHealth McGovern Medical School
Houston, Texas, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Speaker(s)

Lorena Diaz, PhD

Associate Professor
Universidad El Bosque
Bogota, Cundinamarca, Colombia

I do not have any relevant financial / non-financial relationships with any proprietary interests.
William Miller, MD

Assistant Professor
Internal Medicine
Center for Antimicrobial Resistance and Microbial Genomics, UTHealth
Houston, Texas, United States

Entasis (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Grant/Research Support
Jose Munita, MD

Associate Professor
Facultad de Medicina Clinica Alemana Universidad del Desarrollo
Genomics and Resistant Microbes (GeRM) Group. Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R)
Santiago, Region Metropolitana, Chile

Pfizer (Individual(s) Involved: Self): Grant/Research Support

Participants should be aware of the following financial/non-financial relationships:

Julia A. Messina, MD, MHS, MS: Uptodate (Individual(s) Involved: Self): Author, Other Financial or Material Support

Truc Cecilia Tran, PharmD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Lorena Diaz, PhD : I do not have any relevant financial / non-financial relationships with any proprietary interests.

William R. Miller, MD : Entasis (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Grant/Research Support

Jose M. Munita, MD: Pfizer (Individual(s) Involved: Self): Grant/Research Support

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

review global population structure of vancomycin-resistant enterococci
discuss the mechanisms and impact of resistance for vancomycin-resistant enterococci
identify the most current therapeutic options for vancomycin-resistant enterococci

Presentations:

A Quick Glance at the Global VRE Population Structure
Speaker: Lorena Diaz, PhD – Universidad El Bosque
Novel Mechanisms of Resistance in VRE
Speaker: William R. Miller, MD – Center for Antimicrobial Resistance and Microbial Genomics, UTHealth
Treatment of VRE Bacteremia: What You Need to Know
Speaker: Jose M. Munita, MD – Genomics and Resistant Microbes (GeRM) Group. Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R)